scholarly journals Meta-analysis for the Relationship Between Hyperuricemia and CVD Incidence

2021 ◽  
Author(s):  
YEYI YANG ◽  
CHUNJIAO LONG ◽  
ZUOCHENG YANG ◽  
YEZHEN YANG
Keyword(s):  
Uric Acid ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Outcome Indicators ◽  
Risk Of Death ◽  
The Past ◽  
Increased Risk ◽  
Endogenous Antioxidant ◽  
The Relationship ◽  
Exact Relationship

Abstract BACKGROUND: Uric acid was once considered an effective endogenous antioxidant, but now more and more evidence shows that it may play a significant role in the pathophysiology of cardiovascular diseases.OBJECTIVES: It has not been clear that UA is a sign of poor prognosis or a risk factor for CVD. Our aim is to figure out the exact relationship between CVD and uric acid. METHODS: We studied 3356 publications in the past 44 years through MEDLINE, EMBASE, and Cochrane library searches, and selected 22 studies that met our inclusion criteria. RESULTS: The meta-analysis showed that hyperuricemia was associated with an increased risk of death from CVD (RR=1.37; 95% CI:1.29-1.45; I2=31.4%, P=0.157). Sensitivity analysis reviewed several potential sources of heterogeneity between studies, such as average SUA level, study location, and outcome indicators.

scholarly journals Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Yanli Liu ◽  
Yilong Pan ◽  
Yuyao Yin ◽  
Wenhao Chen ◽  
Xiaodong Li
Keyword(s):  
Fixed Effects ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Risk Of Death ◽  
Potential Association ◽  
Increased Risk ◽  
Language Restriction ◽  
Newcastle Ottawa Scale

Abstract Background The numbers of confirmed cases of coronavirus disease 2019 (COVID-19) and COVID-19 related deaths are still increasing, so it is very important to determine the risk factors of COVID-19. Dyslipidemia is a common complication in patients with COVID-19, but the association of dyslipidemia with the severity and mortality of COVID-19 is still unclear. The aim of this study is to analyze the potential association of dyslipidemia with the severity and mortality of COVID-19. Methods We searched the PubMed, Embase, MEDLINE, and Cochrane Library databases for all relevant studies up to August 24, 2020. All the articles published were retrieved without language restriction. All analysis was performed using Stata 13.1 software and Mantel–Haenszel formula with fixed effects models was used to compare the differences between studies. The Newcastle Ottawa scale was used to assess the quality of the included studies. Results Twenty-eight studies involving 12,995 COVID-19 patients were included in the meta-analysis, which was consisted of 26 cohort studies and 2 case–control studies. Dyslipidemia was associated with the severity of COVID-19 (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.11–1.44, P = 0.038, I2 = 39.8%). Further, patients with dyslipidemia had a 2.13-fold increased risk of death compared to patients without dyslipidemia (95% CI 1.84–2.47, P = 0.001, I2 = 66.4%). Conclusions The results proved that dyslipidemia is associated with increased severity and mortality of COVID-19. Therefore, we should monitor blood lipids and administer active treatments in COVID-19 patients with dyslipidemia to reduce the severity and mortality.

Serum uric acid levels and risk of prehypertension: a meta-analysis

2017 ◽  
Vol 55 (3) ◽  
Author(s):  
Menglin Jiang ◽  
Dandan Gong ◽  
Yu Fan
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Meta Analysis ◽  
Elevated Serum ◽  
China National Knowledge Infrastructure ◽  
Cross Sectional ◽  
Knowledge Infrastructure ◽  
Increased Risk ◽  
Cross Sectional Studies ◽  
The Relationship

AbstractElevated serum uric acid (SUA) levels may increase the risk of prehypertension. However, the findings from these studies remain conflicting. The objective of this study was to determine the relationship between SUA levels and risk of prehypertension by conducting a meta-analysis. We conducted a comprehensive literature search of PubMed, Embase, China National Knowledge Infrastructure, VIP, and the Wangfang database without language restrictions through May 2015. Observational studies assessing the relationship between SUA levels and prevalence of prehypertension were included. Pooled adjust odds ratio (OR) and corresponding 95% confidence intervals (CI) of prehypertension were calculated for the highest vs. lowest SUA levels. Prehypertension was defined as systolic blood pressure (BP) ranging from 120 to 139 mmHg or diastolic BP ranging from 80 to 89 mmHg. Eight cross-sectional studies with a total of 21,832 prehypertensive individuals were included. Meta-analysis showed that elevated SUA levels were associated with increased risk of prehypertension (OR: 1.84; 95% CI: 1.42–2.38) comparing the highest vs. lowest level of SUA levels. Subgroup analyses showed that elevated SUA levels significantly increased the risk of prehypertension among men (OR: 1.60; 95% CI: 1.12–2.21) and women (OR: 1.59; 95% CI: 1.17–2.16). Elevated SUA levels are positively associated with the risk of prehypertension in the general population. However, more well-designed longitudinal studies are needed before a definitive conclusion can be drawn due to the cross-sectional studies included are susceptible to bias.

scholarly journals The relationship between Fas and Fas ligand gene polymorphism and preeclampsia risk

2019 ◽  
Vol 39 (2) ◽  
Author(s):  
Tingting Wang ◽  
Yunyun Lian
Keyword(s):  
Fas Ligand ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Nucleotide Polymorphisms ◽  
Multisystem Disorder ◽  
Increased Risk ◽  
Fasl Gene ◽  
The Cochrane Library ◽  
The Relationship ◽  
Risk Of Preeclampsia

Abstract Preeclampsia is an idiopathic multisystem disorder with partial genetic and immunological etiology. Several studies investigated the association between various single-nucleotide polymorphisms (SNPs) in Fas and Fas ligand (FasL) genes and the risk of preeclampsia. However, they achieved inconsistent results. Therefore, we conducted a meta-analysis by systematically searching the Cochrane Library, PubMed and Embase databases and assessed this association by calculating pooled odds ratios with 95% confidence interval to reach a more trustworthy conclusion. Subgroup analyses by genotype methods and source of controls (SOC) were also conducted. Seven citations containing nine studies were included for four SNPs (Fas -670 A/G, FasL 124A/G, FasL -844C/T, Fas -1377 G/A) in this meta-analysis. Our data suggested the G allele and genotype GG of the Fas -670 A/G polymorphism, GG genotype of the FasL 124A/G polymorphism, and TT genotype of the FasL -844C/T polymorphism increased the risk of preeclampsia. Stratification analyses by genotype methods and SOC also indicated that Fas -670 A/G polymorphism was related to increased risk for preeclampsia. In conclusion, Fas and FasL gene polymorphisms play important roles in the development of preeclampsia. Further well-designed studies in other races are needed to confirm the findings of this meta-analysis.

scholarly journals Urolithiasis, Independent of Uric Acid, Increased Risk of Coronary Artery and Carotid Atherosclerosis: A Meta-Analysis of Observational Studies

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Wei Luo ◽  
Yao Zhou ◽  
Chenlin Gao ◽  
Pijun Yan ◽  
Ling Xu
Keyword(s):  
Uric Acid ◽  
Coronary Artery ◽  
Serum Uric Acid ◽  
Observational Studies ◽  
Carotid Atherosclerosis ◽  
Meta Analysis ◽  
Renal Calculi ◽  
Cochrane Library ◽  
Increased Risk ◽  
Cv Disease

Background and Aims. Recent epidemiological evidence indicates an association between urolithiasis and atherosclerosis; however, results are incongruous. Our aim is to summarize the association between urolithiasis and arteriosclerosis risk through a detailed meta-analysis. Methods. Relevant studies published before April 2019 were identified by searching OVID, EMBASE, PubMed, Web of Science database, and Cochrane Library. The relationship between urolithiasis and the risk of atherosclerosis was assessed by using odds ratio (OR) values and the corresponding 95% confidence intervals (CIs), and the selection of fixed- or random-effects model based on heterogeneity. Results. The meta-analysis includes 8 observational studies that contained 70,716 samples. Pooled results showed that urolithiasis was associated with an increased adjusted and unadjusted risk estimated for atherosclerosis (P=0.017 and P=0.014, respectively), especially in coronary artery and carotid atherosclerosis, which was associated with the outcome of CV disease. Interestingly, when we merged the data from the vast majority of these samples (n = 65,751/70,716) with serum uric acid levels less than 6.0 mg/dl, it still showed that urolithiasis was associated with a higher risk of atherosclerosis (P<0.001) and with no evidence of heterogeneity (I2 = 0.0%, P=0.697). Furthermore, we also found that renal calculi would increase the risk of moderate or severe atherosclerosis (P<0.001) and recurrent renal calculi were associated with the incidence of atherosclerosis (P=0.007). Conclusions. Urolithiasis is associated with an increased risk for atherosclerosis, especially in coronary artery and carotid atherosclerosis. Urolithiasis may be another potential risk factor of atherosclerosis, which is independent of serum uric acid levels.

scholarly journals Association between GABRG2 rs211037 polymorphism and febrile seizures: a meta-analysis

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Xiaohui Yang ◽  
Jing Chi ◽  
Xiaomeng Wang ◽  
Hongyun Wei ◽  
Xueping Zheng ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Febrile Seizures ◽  
Random Model ◽  
Cochrane Library ◽  
Asian Populations ◽  
Increased Risk ◽  
Subgroup Analyses ◽  
Relationship Of ◽  
The Relationship ◽  
Age And Sex

Abstract Background Emerging evidence has implied that the GABRG2 gene play a role in the mechanism of febrile seizure (FS), however, the relationship between GABRG2 rs211037 polymorphism and the risk of FS remains controversial. This meta-analysis was conducted to investigate the relationship of GABRG2 rs211037 polymorphism with the susceptibility to FS. Methods MEDLINE, Embase, Cochrane Library and CNKI databases were searched (until April 6, 2019) for eligible studies on the relationship between GABRG2 rs211037 polymorphism and FS. We calculated the odds ratios (ORs) by a fixed or random model with the STATA 15.0 software. Subgroup analyses for the ethnicity, the source of the control, and age and sex matching of controls were conducted. Results A total of 8 studies consisting of 775 FS patients and 5162 controls were included in this study. Based on the overall data, he GABRG2 rs211037 polymorphism was not significantly associated with the risk of FS (TT + CT vs CC: OR = 0.95, 95%CI 0.64–1.41, P = 0.80). Notably, the GABRG2 rs211037 variant was significantly associated with decreased risk of FS in Asian populations (TT vs CT + CC: OR = 0.63, 95%CI 0.45–0.88, P = 0.006), but increased risk in Caucasian populations (CT vs CC: OR = 1.56, 95%CI 1.14–2.15, P = 0.006). Significant associations were also detected when healthy controls out of the whole controls were employed for comparison (TT vs CT + CC: OR = 0.59, 95% CI 0.45–0.77, P < 0.001) and when data from studies with age- and sex-matched controls were used (TT + CT vs CC: OR = 0.60, 95% CI 0.43–0.86, P = 0.001). Conclusion The GABRG2 rs211037 polymorphism may decrease the risk of FS in Asian populations, while increasing the risk in Caucasian populations. Further well-designed studies with large sample sizes are essential to verify the conclusions in other ethnicities.

scholarly journals The Relationship between Age-Related Macular Degeneration and Cardiovascular Disease: A Meta-Analysis

2021 ◽  
Author(s):  
Jungmin LEE ◽  
Heuy Sun SUH ◽  
In Cheol HWANG
Keyword(s):  
Cardiovascular Disease ◽  
Macular Degeneration ◽  
Publication Bias ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Cochrane Library ◽  
Age Related ◽  
Increased Risk ◽  
Clinical Benefits ◽  
The Relationship

Background: Age-related macular degeneration (AMD) and cardiovascular disease (CVD) share pathogenic mechanisms, and their lead-lag relationship remains unclear. We performed a meta-analysis of data from longitudinal studies to evaluate the interactive association between age-related macular degeneration (AMD) and cardiovascular disease (CVD). Methods: A literature search was performed in PubMed, Embase, and Cochrane Library up to Feb 2019. Estimates were pooled by study quality and type of AMD and CVD. Publication bias was assessed by Begg’s test. Results: We identified nine studies for the risk of AMD in CVD and ten studies for the risk of CVD in AMD. Overall, evidence for the risk of CVD in AMD patients was most robust. Both early and late AMD preceded CVD, but more solid significance existed in late AMD. Among the types of CVD, stroke was more tightly associated with AMD than coronary heart disease. Publication bias was not significant in either direction. Conclusion: AMD is a risk factor for CVD, which is primarily driven by the increased risk of stroke in patients with late AMD. Moreover, these results suggested that AMD treatment and screening for CVD in AMD patients may have unexplored clinical benefits.

scholarly journals The relationship between metabolic syndrome and increased risk of Barrett's esophagus: An Updated systematic review and meta-analysis

2020 ◽  
Author(s):  
Mohammad Karimian ◽  
Majid Salamati ◽  
Milad Azami
Keyword(s):  
Metabolic Syndrome ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Meta Analysis ◽  
Cochrane Library ◽  
P Value ◽  
Control Groups ◽  
Increased Risk ◽  
Study Type ◽  
The Relationship

Abstract Background: The relationship between metabolic syndrome ( MetS) and Barrett's esophagus (BE) is still a challenging issue, and inconsistent results have been reported in different studies. Therefore, this study was conducted to determine the relationship between MetS and BE. Methods : In this study, we followed the MOOSE protocol and the PRISMA guidelines for reporting the results. All study steps were performed independently by two authors. If necessary, the dispute was resolved by consultation with a third author. The search strategy is designed to find published studies. Comprehensive search was done in the following biomedical databases until July 2019: Cochrane Library, PubMed/Medline, Web of Science, Science Direct, EMBASE, Scopus, CINAHL, EBSCO, and Google Scholar search engine. All analyses were performed using Comprehensive Meta-Analysis Software Ver.2, while p-value lower than 0.05 was considered significant. Results : In 14 studies with a sample size of 108416, MetS significantly increased the risk of BE (OR=1.315; 95% CI: 1.110-1.558; P<0.001; Heterogeneity: I 2 = 81.55; P<0.001). Sensitivity analysis by omitting one study showed that overall estimates are still robust. Subgroup analysis was significant for continent (P<0.001) and MetS diagnostic criteria (P=0.043), but was not significant for variables of study type (P=0.899), study setting (P=0.115), control groups (P=0.671) and quality of studies (P=0.603). The Begg (P=0.912) and Egger's (P=0.094) tests were not significant; therefore, the publication bias did not play a role in the results. Conclusion: MetS increases the risk of BE compared to control groups. Future studies should examine whether treatment for metabolic syndrome reduces the risk of BE.

scholarly journals The Relationship between Helicobacter pylori Infection of the Gallbladder and Chronic Cholecystitis and Cholelithiasis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Liang Wang ◽  
Junyin Chen ◽  
Wenxi Jiang ◽  
Li Cen ◽  
Jiaqi Pan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Helicobacter Pylori ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Chronic Cholecystitis ◽  
Cochrane Library ◽  
Positive Correlation ◽  
Increased Risk ◽  
H Pylori ◽  
The Relationship

Helicobacter pylori (H. pylori) is proved to be the main pathogenic agent of various diseases, including chronic gastritis, gastric ulcer, duodenal ulcer, and gastric cancer. In addition, chronic cholecystitis and cholelithiasis are common worldwide, which are supposed to increase the total mortality of patients. Epidemiologic evidence on the relationship between H. pylori infection of the gallbladder and chronic cholecystitis/cholelithiasis still remains unclear. We conducted a systematic review and meta-analysis of overall studies to investigate the relationship between H. pylori infection of the gallbladder and chronic cholecystitis/cholelithiasis. Two researchers searched PubMed, Embase, and Cochrane Library databases to obtain all related and eligible studies published before July 2020. The pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated by the random-effects model. Subgroup analysis, heterogeneity, publication bias, and sensitivity analysis were also conducted. Twenty studies were included in the meta-analysis, involving 1735 participants and 1197 patients with chronic cholecystitis/cholelithiasis. Helicobacter species infection of the gallbladder was positively correlated with increased risk of chronic cholecystitis and cholelithiasis, especially H. pylori (OR = 3.05; 95% CI, 1.81–5.14; I2 = 23.5%). Besides, country-based subgroup analysis also showed a positive correlation between the gallbladder H. pylori positivity and chronic cholecystitis/cholelithiasis risk. For Asian and non-Asian country studies, the ORs were 4.30 (95% CI, 1.76–10.50; I2 = 37.4%) and 2.13 (95% CI, 1.23–3.70; I2 = 0.0%), respectively. The association was more obvious using the bile sample and urease gene primer. In conclusion, this meta-analysis provided evidence that there is a positive correlation between H. pylori infection in the gallbladder and increased risk of chronic cholecystitis and cholelithiasis.

scholarly journals The prevalence and clinical features of pulmonary embolism in patients with AE-COPD: A meta-analysis and systematic review

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0256480
Author(s):  
Xiaofang Fu ◽  
Yonghong Zhong ◽  
Wucheng Xu ◽  
Jiangang Ju ◽  
Min Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pulmonary Embolism ◽  
Confidence Intervals ◽  
Meta Analysis ◽  
Fatal Outcome ◽  
Cochrane Library ◽  
Chronic Obstructive ◽  
Risk Of Death ◽  
Copd Patients ◽  
Increased Risk

Background The prevalence of pulmonary embolism (PE) in the acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) is highly controversial. We conducted a systematic review and meta-analysis to summarize the epidemiology and characteristics of PE with AE-COPD for current studies. Methods We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases for studies published prior to October 21, 2020. Pooled proportions with 95% confidence intervals (95% CIs) were calculated using a random effects model. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals were used as effect measures for dichotomous and continuous variables, respectively. Results A total of 17 studies involving 3170 patients were included. The prevalence of PE and deep vein thrombosis (DVT) in AE-COPD patients was 17.2% (95% CI: 13.4%-21.3%) and 7.1% (95% CI: 3.7%-11.4%%), respectively. Dyspnea (OR = 6.77, 95% CI: 1.97–23.22), pleuritic chest pain (OR = 3.25, 95% CI: 2.06–5.12), lower limb asymmetry or edema (OR = 2.46, 95% CI:1.51–4.00), higher heart rates (MD = 20.51, 95% CI: 4.95–36.08), longer hospital stays (MD = 3.66, 95% CI: 3.01–4.31) were associated with the PE in the AE-COPD patients. Levels of D-dimer (MD = 1.51, 95% CI: 0.80–2.23), WBC counts (MD = 1.42, 95% CI: 0.14–2.70) were significantly higher and levels of PaO2 was lower (MD = -17.20, 95% CI: -33.94- -0.45, P<0.05) in the AE-COPD with PE group. The AE-COPD with PE group had increased risk of fatal outcome than the AE-COPD group (OR = 2.23, 95% CI: 1.43–3.50). Conclusions The prevalence of PE during AE-COPD varies considerably among the studies. AE-COPD patients with PE experienced an increased risk of death, especially among the ICU patients. Understanding the potential risk factors for PE may help clinicians identify AE-COPD patients at increased risk of PE. Prospero registration number CRD42021226568.

scholarly journals Comorbidities increase the risk of severity and mortality in COVID-19 patients: a systematic review and meta-analysis

2021 ◽  
Vol 10 (2) ◽  
pp. e50010212533
Author(s):  
Edilson Leite de Moura ◽  
Jean Moises Ferreira ◽  
Ana Caroline Melo dos Santos ◽  
Denise Macedo da Silva ◽  
Maria Lidiane Ferreira da Silva ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cerebrovascular Diseases ◽  
Poor Clinical Outcome ◽  
Random Effects Models ◽  
Risk Of Death ◽  
Increased Risk ◽  
Retrospective Cohort Studies ◽  
The Relationship

Introduction: Several studies have shown that patients with comorbidities present a poor clinical outcome of COVID-19, but the conclusions are not yet consolidated. We conducted a meta-analysis to evaluate the relationship between the preexistent conditions (comorbidities) in patients infected with SARS-CoV-2 and the outcome of COVID-19. Methods: PubMed, Science Direct, ISI Web of Science and Scopus databases were examined up to November 2020. We calculated the pooled odds ratio (OR) with 95% confidence interval, using fixed-effects or random-effects models. Results: A total of 48 retrospective cohort studies with 344,290 COVID-19 patients were included in the meta-analysis. The pooled results showed that hypertension, diabetes, cardiovascular, chronic pulmonary, chronic kidney and cerebrovascular diseases increase the risk of severity and mortality in COVID-19 patients. Moreover, malignancy was associated with an increased risk of death from COVID-19. Conclusions: The comorbidities previously mentioned may be important predictors of poor outcome of COVID-19, contributing to the prognosis of severe cases of the disease.

Sign in / Sign up

Export Citation Format

Share Document